AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 233 min read$RDY

Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript

Dr. Reddy's reported Q2 2027 earnings with a 52.1% gross margin increase sequentially but a 254 basis point year-over-year decline due to lower Lenalidomide sales. EBITDA margin was 20.6%, and profit after tax was ₹9.25 crores. The company highlighted double-digit growth in North America and emerging markets, new product launches, and strategic partnerships. Operating working capital increased to $1.53 billion, with a net cash surplus of ₹2.5 thousand crores.

Original reporting
finance.yahoo.com
Published Oct 23, 2026, 4:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RDYNeutralMed
01

Why it matters

The earnings provide fresh data on revenue mix, margins and EPS, informing valuation and sector outlook.

02

Market read

First disclosure of quarterly results; moderate relevance for traders with exposure to emerging‑market pharma.

03

What to watch

Impact of Middle East supply‑chain disruptions and upcoming semaglutide reload may boost future quarters.

Relevance 7/10Novelty 7/10Timing: post-market

Background

Dr. Reddy's (RDY) released its Q2 FY27 earnings call transcript, detailing financial performance across segments.

Company-level read

Ticker impact

$RDYNeutralMedium confidence
Context

Q2 FY27 earnings call disclosed revenue, margin and EPS figures for the first time.

Expected impact

potential slight downside as margins dip and revenue growth slows in Europe.

Evidence & confidence

First release of quarterly numbers provides new data, but no dramatic surprise; investors may adjust valuations modestly.

Market effects

Sector

Highlights pressure on Indian pharma generics margins and potential re‑rating of sector peers.

Regional

May influence Indian market sentiment and affect other domestic pharma stocks.

Global

Limited; primarily relevant to investors in emerging‑market pharma exposure.

Counterpoint

What could challenge this read

Despite margin compression, strong growth in emerging markets could support upside.

Key entities

  • company
    Dr. Reddy's Laboratories Ltd.

    Indian pharmaceutical company listed in the US as RDY.

Read at source← All news

StoryDr. Reddy's Laboratories posts Q2 FY27 revenue decline and profit slump

Also covered by

3 outlets

Related articles

OCT 23
$RDYMed

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE: RDY) expects to relaunch semaglutide in November 2026, with most supply going to Canada. Q2 North America generics revenue was $264M, down 29% YoY. The company received FDA approval for its rituximab biosimilar and launched nivolumab in India. Net cash as of Sept. 30 was INR 2,502 crore, with full-year capex expected at INR 1,600-1,700 crore.

finance.yahoo.com3 min
OCT 23
$RDYHigh

Dr. Reddy's Laboratories (RDY) Stock Falls on Q2 2027 Earnings

Dr. Reddy's Laboratories (RDY) reported Q2 2027 earnings with revenue down 8.8% to $903.9M, operating profit down 71.6% to $132.2M, and net income down 40.4% to $96.4M. Cash from operations fell 67.4% to $55.2M. The stock dropped 2.69% in morning trading. Institutional investors showed mixed activity, with some adding and others reducing their positions.

quiverquant.com1 min
OCT 23
$RDYMed

Dr. Reddy’s Q2FY27 slides: base growth masks lenalidomide drag

Dr. Reddy’s Laboratories reported fiscal Q2 2027 revenues of ₹8,671 crores, down 1.5% YoY but up 7% sequentially. EBITDA margin was 20.6%, with profit after tax at ₹925 crores. North America sales declined 23% YoY due to lenalidomide, but other regions showed growth. The company announced strategic partnerships and product developments, including a dengue vaccine and biosimilars. Shares rose 0.45% to $13.29 post-results.

investing.com2 min
OCT 23
$RDYMed

Dr. Reddy's Laboratories Profit Drops In Q2

Dr. Reddy's Laboratories reported a 36% drop in Q2 profit to INR 9,134 million, or INR 11.10 per share, from the prior year. Revenue declined to INR 86,708 million, driven by lower lenalidomide sales in North America. Pre-market trading showed a 0.76% increase to $13.32 on the NYSE.

rttnews.com1 min
AUG 14
$RDYMed

Dr. Reddy's Hyderabad Facility Receives Four Observations from USFDA

Dr. Reddy’s Laboratories said the US FDA inspected its Hyderabad formulations facility FTO-3 (Bachupally) from Aug 6-14, 2026 and issued a Form 483 listing four observations. The company must prepare and implement a remediation plan within the US FDA’s timeline. Investors may watch for updates on corrective actions and closure.

whalesbook.com2 min